Restoring fertility
to aged eggs.
We're redefining fertility possibilities by improving egg quality, integrating seamlessly with current IVF protocols.
Women deserve better fertility solutions
Millions of women worldwide face the heartbreaking challenge of age-related infertility. While current IVF protocols are advanced, treatment success rates drop sharply for women in their mid-30’s to 40’s.
A typical IVF journey involves multiple cycles that are often unsuccessful. The need for several IVF cycles not only increases financial costs, but significantly prolongs the difficult journey patients go through to have a child, making the process inaccessible and unsustainable for many.
Price and age shouldn't limit fertility options
Improving successful IVF outcomes, in just one cycle.
At U-Ploid Biotechnologies, we’re dedicated to significantly improving the IVF journey for women later in life. We’re developing treatments that are designed to improve the quality of older egg cells, and in doing so addressing the growing unmet need for age-related infertility treatments.
Designed to integrate with IVF workflows.
Our mission is to radically improve IVF outcomes, and remove barriers to accessing effective care. That’s why we're developing a highly-scalable solution that allows for effective integration into clinics worldwide.
Latest news
-
![]()
PR Newswire
September 2024 | U-Ploid announces breakthrough technology to overcome age-related infertility.
-
![]()
Bioescalator
August 2024 | U-Ploid Biotechnologies joins the BioEscalator to develop groundbreaking therapeutics that improve egg quality and revolutionise IVF.
-
![]()
Cambridge Independent
July 2024 | U-Ploid Biotechnologies recently showcased its groundbreaking IVF therapeutics at the Accelerate@Babraham Pitch Day.
-
![]()
Business Weekly
June 2024 | Six life science start-ups looking to develop products and services to make a positive difference to healthcare have been selected for one of Europe’s top incubators based at the Babraham Research Campus in Cambridge.
-
![]()
Cambridge Independent
May 2024 | The six start-ups making up the 2024 Accelerate@Babraham cohort unveiled.
Our Team
-
Co-Founder & Chief Executive Officer
Jordan Abdi is a medical doctor and entrepreneur, and co-founded U-Ploid to revolutionise fertility care. With a background in supporting biopharma and life science companies, he has a proven track record of navigating complex regulatory landscapes and market access challenges across Europe, China, and the United States.
-
Co-Founder & Chief Operating Officer
Chloe Charalambous has a background in reproductive cell biology and co-founded U-Ploid with a passion for advancing reproductive healthcare. She has expertise in pre-clinical research and development, and a deep understanding of the challenges and opportunities in the fertility sector.
-
Co-Founder & Chief Scientific Officer
Alex is an experienced reproductive molecular biologist. His research focuses on genome maintenance and chromosome structures in animal eggs, with special interest for bioengineering solutions supporting egg development. His previous role as a visiting scientist at the Bourn Hall Fertility Clinic (Cambridgeshire, UK) revealed to Alex the difficult journey women undertake when trying to conceive by assisted reproduction. This experience motivated him to leverage powerful molecular-based innovations to improve fertility healthcare.
Our Advisors
-
Prof. Helen Picton
Head of the Reproduction and Early Development Research Group, University of Leeds
Profile -
Yannick Ferreira, MSc
Founder & CEO Caring IVF
LinkedIn -
Nawal Roy
Founder & CEO Holmusk
LinkedIn -
Prof. Matteo Molè, PhD
Assistant Professor of Obstetrics and Gynecology (Reproductive & Stem Cell Biology) Stanford University
LinkedIn
Our partners
U-Ploid is committed to revolutionising fertility healthcare
For more information:
info@u-ploid.com
For press enquiries, please contact:
press@u-ploid.com
Designed by Superthink